Shilpa Medicare Files First US Transdermal Patch ANDA for Rotigotine, Targeting $112 Million Market
核心洞察
Shilpa Medicare Limited filed its first Abbreviated New Drug Application (ANDA) with the U.S. FDA for a generic Rotigotine transdermal patch system.
The generic version targets Neupro® and is indicated for treating Restless Legs Syndrome (搜索) and Parkinson's disease (搜索) in a market valued at $112 million.
The submission represents a strategic expansion into complex US specialty pharmaceuticals, leveraging the company's USFDA-approved manufacturing facility in Bengaluru.
Shilpa Medicare Limited has achieved a significant regulatory milestone with the filing of its first Abbreviated New Drug Application (ANDA) for Rotigotine Transdermal System, USP, with the U.S. Food and Drug Administration (搜索) (USFDA). This submission marks the company's inaugural transdermal patch filing with the USFDA and represents entry into a substantial $112 million addressable U.S. market.
Generic Alternative to Neupro®
The generic Rotigotine transdermal patch system is designed as a pharmaceutical and bioequivalent alternative to the innovator product Neupro®. Available in multiple strengths (1, 2, 3, 4, 6, 8 mg/24 h), the patches are indicated for the treatment of Restless Legs Syndrome (搜索) and Parkinson's disease (搜索). The total addressable US market for Rotigotine is estimated at USD 112 million, approximately ₹929 crore.
Advanced Manufacturing Capabilities
The ANDA submission originates from Shilpa Medicare's finished dosage form manufacturing facility, Unit VI, located in Dobbaspet, Bengaluru, Karnataka. This facility has received approval from both European and USFDA authorities and specializes in manufacturing, packaging, labeling, and testing of specialized finished dosage forms, including oral dispersible/dissolving films and transdermal patches.
Strategic Market Positioning
The filing underscores Shilpa Medicare's strategic focus on expanding its presence in the US specialty pharmaceutical segment, leveraging established expertise in complex generics and novel drug delivery systems. Transdermal patches represent a complex dosage form that offers patient-friendly administration through once-daily application and ensures sustained, controlled release of medication.
The successful development and submission of this complex dosage form represents a significant achievement for the company, highlighting its manufacturing and R&D capabilities for specialized finished dosage forms in the competitive US pharmaceutical market.